Table 1 |
||
|
Pathological and clinical characteristics |
||
|
Variable |
All triple negatives; n = 97 (%) |
Triple negatives with sufficient FU; n = 71 (%) |
|
|
||
|
Age (years) |
||
|
<41 |
24 (25) |
18 (25) |
|
41–50 |
33 (34) |
30 (42) |
|
>50 |
40 (41) |
23 (32) |
|
Tumor size (cm) |
||
|
≤2.0 |
34 (35) |
23 (32) |
|
>2.0 |
63 (65) |
48 (68) |
|
Number of tumor positive lymph nodes |
||
|
0 |
54 (56) |
35 (49) |
|
1–3 |
29 (30) |
26 (37) |
|
>3 |
14 (14) |
10 (14) |
|
Tumor subtype |
||
|
Adenoid cystic |
4 (4) |
NA |
|
Apocrine |
7 (7) |
7 (10) |
|
Ducto-lobular |
1 (1) |
NA |
|
IDC (nos) |
81 (83) |
63 (89) |
|
ILC |
1 (1) |
1 (1) |
|
Metaplastic |
3 (3) |
NA |
|
Tumor shape |
||
|
Multi-nodular |
4 (4) |
4 (6) |
|
Stellate |
17 (18) |
12 (17) |
|
Sharply demarcated/lobulated |
76 (78) |
55 (76) |
|
Histological grade |
||
|
1 |
2 (2) |
2 (3) |
|
2 |
8 (8) |
4 (6) |
|
3 |
83 (86) |
65 (92) |
|
Adenoid cystic carcinoma not graded |
4 (4) |
NA |
|
DCIS component around tumor |
||
|
None |
79 (81) |
56 (79) |
|
Minimal |
10 (10) |
8 (11) |
|
Moderate |
8 (8) |
7 (10) |
|
Extensive |
NA |
NA |
|
DCIS differentiation grade |
||
|
Well |
1 (6) |
1 (7) |
|
Moderate |
NA |
NA |
|
Poor |
17 (94) |
14 (93) |
|
LCIS component |
||
|
None |
93 (96) |
67 (94) |
|
Present |
4 (4) |
4 (6) |
|
Vascular invasion |
||
|
None |
84 (87) |
59 (83) |
|
Present |
13 (13) |
12 (17) |
|
Lymphocytic infiltrate |
||
|
None |
8 (8) |
4 (6) |
|
Minimal |
40 (41) |
34 (48) |
|
Moderate |
33 (34) |
25 (35) |
|
Extensive |
12 (12) |
8 (11) |
|
Adenoid cystic carcinoma not graded |
4 (4) |
NA |
|
Central fibrotic zone |
||
|
None |
44 (45) |
31 (44) |
|
Present |
49 (51) |
40 (56) |
|
Adenoid cystic carcinoma not graded |
4 (4) |
NA |
|
KRT5/6 |
||
|
Negative (0% staining) |
21 (22) |
16 (23) |
|
Positive (> 0% staining) |
74 (76) |
53 (75) |
|
Unknown |
2 (2) |
2 (3) |
|
p53 |
||
|
Negative (< 50% staining) |
47 (49) |
33 (47) |
|
Positive (> 49% staining) |
48 (50) |
36 (51) |
|
Unknown |
2 (2) |
2 (3) |
|
EGFR |
||
|
Negative (0% staining) |
69 (71) |
58 (82) |
|
Positive (> 0% staining) |
26 (27) |
11 (16) |
|
Unknown |
2 (2) |
2 (3) |
|
KIT |
||
|
Negative (0% staining) |
58 (60) |
39 (55) |
|
Positive (> 0% staining) |
37 (38) |
30 (42) |
|
Unknown |
2 (2) |
2 (3) |
|
Treatment of primary tumor |
||
|
Breast-conservation |
61 (63) |
45 (63) |
|
Mastectomy |
36 (37) |
26 (37) |
|
Adjuvant radiotherapy |
||
|
Yes |
85 (88) |
65 (92) |
|
No |
12 (12) |
6 (8) |
|
Adjuvant systemic therapy |
||
|
Chemotherapy |
47 (48) |
37 (52) |
|
Endocrine therapy |
13 (13) |
11 (15) |
|
Chemotherapy and endocrine therapy |
4 (4) |
4 (6) |
|
None |
33 (34) |
19 (27) |
|
Metastasis as first event |
||
|
Yes |
NA |
17 (24) |
|
No |
NA |
54 (76) |
|
|
||
|
DCIS, ductal carcinoma in situ; EGFR, epidermal growth factor receptor; FU, follow-up; IDC (nos), infiltrating ductal carcinoma (not otherwise specified); ILC, infiltrating lobular carcinoma; LCIS, lobular carcinoma in situ; NA, not applicable. |
||
|
Kreike et al. Breast Cancer Research 2007 9:R65 doi:10.1186/bcr1771 |
||
